Clarity Advances Late-Stage Radiopharmaceutical Pipeline on Strong Cash Base

The latest update is out from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ).

Clarity Pharmaceuticals reported a strong cash position of $226.2 million as of 31 December 2025, underpinning its ability to advance multiple late-stage clinical programs. In its SECuRE Phase II trial of 67Cu-SAR-bisPSMA for prostate cancer, an interim review by the Safety Review Committee supported continuation without protocol changes, with data showing a favourable safety profile and promising efficacy, including substantial PSA reductions in all evaluable patients and one case of undetectable disease on imaging. The Co-PSMA investigator-initiated trial demonstrated that 64Cu-SAR-bisPSMA detected significantly more PSMA-positive lesions than the current standard-of-care 68Ga-PSMA-11 PET/CT in patients with biochemical recurrence and low PSA, reinforcing the competitive potential of Clarity’s diagnostic platform. Additionally, following a successful End-of-Phase meeting with the US FDA, Clarity is set to begin a pivotal Phase III registrational trial of its 64Cu-SARTATE diagnostic agent in neuroendocrine tumours in 2026, marking a key step toward potential regulatory approval and commercial entry in this indication.

The most recent analyst rating on (AU:CU6) stock is a Hold with a A$3.50 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.

More about Clarity Pharmaceuticals Ltd.

Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing copper-based imaging and targeted therapeutic products for oncology, including prostate cancer and neuroendocrine tumours, with a strategy aimed at progressing its pipeline toward commercialisation in global markets.

Average Trading Volume: 2,175,901

Technical Sentiment Signal: Sell

Current Market Cap: A$1.29B

For detailed information about CU6 stock, go to TipRanks’ Stock Analysis page.